US12605402B2 Oxidizing Acid Solution Patent Grant

The USPTO issued patent US12605402B2 to APR Applied Pharma Research SA, granting exclusive rights to therapeutic methods using hypotonic acid oxidizing solutions containing hypochlorous acid for five distinct indications: Epidermolysis Bullosa, EGFR inhibitor-induced skin toxicities, Hailey-Hailey Disease, Buruli Ulcers, and SARS-CoV-2 infections. The patent covers topical application to affected areas and contains 22 claims spanning multiple CPC classifications.

Pharmaceutical and medical device companies developing competing topical acid-based therapeutic products for any of the listed indications should conduct patent clearance analyses to assess potential infringement exposure. Generic or biosimilar developers targeting these conditions may need to explore design-around strategies or licensing arrangements with the patent holder. The scope of this patent across five therapeutic areas is substantive, affecting competitive dynamics in multiple treatment markets.